Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 36

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 36
---
must consult their own banks, brokers or other financial institutions to find out how to have their interests in securities transferred
to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above.

The global security will terminate
when the following special situations occur:

| · | if the depositary notifies us that it is unwilling,                                                                                             
 unable or no longer qualified to continue as depositary for that global security and we do not appoint another institution to act as depositary 
 within 90 days;                                                                                                                                 |

| · | if we notify any applicable trustee that we wish 
 to terminate that global security; or            |

| · | if an event of default has occurred with regard                                     
 to securities represented by that global security and has not been cured or waived. |

The applicable prospectus
supplement may also list additional situations for terminating a global security that would apply only to the particular series of securities
covered by the prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible
for deciding the names of the institutions that will be the initial direct holders.

<div align='center'>25

PLAN OF DISTRIBUTION</div>

We may sell our securities
covered by this prospectus in any of three ways (or in any combination):

| · | to or through underwriters or dealers; |

| · | directly to one or more purchasers; or |

| · | through agents. |

We may distribute the securities:

| · | from time to time in one or more transactions                       
 at a fixed price or prices, which may be changed from time to time; |

| · | “at the market” offerings, as defined                                                                                                      
 in Rule 415 under the Securities Act of 1933, as amended, (the “Securities Act”), at negotiated prices, at prices prevailing               
 at the time of sale or at prices related to such prevailing market prices, including sales made directly on a national securities exchange 
 or sales made through a market maker other than on an exchange or other similar offerings through sales agents; or                         |

| · | at negotiated prices. |

Each time we offer and sell
securities covered by this prospectus, we will provide a prospectus supplement or supplements that will describe the method of distribution
and set forth the terms of the offering, including:

| · | the name or names of any underwriters, dealers 
 or agents;                                     |

| · | the amounts of securities underwritten or